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Gamma-hydroxybutyric acid (GHB) is an endogenous
constituent of the mammalian brain, with GABA being its major
precursor, which readily and rapidly crosses the blood brain
barrier. Nevertheless, GHB is not merely a by-product of GABA
metabolism. It satisfies many of the criteria for consideration as a
neurotransmitter at the central nervous system. In fact, GHB has
its own high and low affinity binding sites in different species, also
modulating dopaminergic and GABAergic activity (Maitre, 1997;
Crunelli, Emri, & Leresche, 2006; García, Pedraza, & Navarro,
2006).
GHB has gained notoriety as a drug of abuse (popularly known
as «liquid ecstasy»). Typically, it is ingested with the intention of
inducing euphoria and relaxation during music festivals or «rave
parties». However, numerous cases of GHB intoxication have been
documented, and symptoms of tolerance, dependence, and
withdrawal have been reported (Drasbek, Christensen, & Jensen,
2006). Furthermore, GHB has earned a reputation as a «date rape»
drug, since its color- and odorless appearance goes unnoticed in
the drinks of the victims, thereby leading to sedation by GHB as a
prelude to the sexual assault (Varela, Nogue, Oros, & Miro, 2004;
Crunelli et al., 2006). 
Exogenously administered GHB induces a wide range of
pharmacological effects in rodents, including sedation, catalepsy
(Navarro et al., 1996; 1998), a decrease of aggression (Navarro &
Pedraza, 1996; Pedraza, Dávila, Martín-López, & Navarro, 2007),
memory impairment (Sircar & Basak, 2004; García, Pedraza,
Arias, & Navarro, 2006), seizures or an increase in sleep stages 3
and 4 (Crunelli et al., 2006). Schmitt-Mutter et al. (1998) reported
an anxiolityc-like effect of GHB in male rats tested in the
«elevated plus maze». However, preliminary results in mice using
the same procedure suggested an anxiogenic-like action of GHB
(Navarro et al., 2000). In this study, an attempt was made to clarify
the anxiolytic/anxiogenic profile of GHB (40, 80 and 120 mg/kg,
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Gamma-hydroxybutyric acid (GHB) is a drug with abuse potential, popularly known as «liquid ecsta-
sy». It is an endogenous compound of the mammalian brain which satisfies many of the criteria for
consideration as a neurotransmitter or neuromodulator. In this study, the effects of acute administration
of GHB (40, 80 and 120 mg/kg, ip) on anxiety, tested in the light/dark box, were examined in male
mice of the OF.1 strain. Likewise, we compared the behavioural profile of GHB with that induced by
mCPP (1 mg/kg, ip), a compound with known anxiogenic actions. GHB-treated mice spent notably less
time in the lit area (40 and 80 mg/kg) and more time in the dark area (all doses), whereas the total num-
ber of ‘rearings’, transitions and latency were significantly reduced. A very similar behavioural profile
was observed in mCPP-treated animals. Overall, these findings indicate that GHB exhibits anxiogenic-
like properties in male mice. It is suggested that the anxiogenic effects of GHB could be related to its
ability to modulate GABA and/or dopaminergic receptors.
Efectos ansiogénicos del ácido gamma-hidroxibutírico (GHB) en ratones evaluados en el test del
«light-dark». El ácido gamma-hidroxibutírico es una droga con potencial de abuso popularmente co-
nocida como «éxtasis líquido». Es un compuesto endógeno presente en el cerebro de mamíferos que
cumple muchos de los criterios para ser considerado como neurotransmisor o neuromodulador. En es-
te estudio examinamos el efecto de la administración aguda de GHB (40, 80 y 120 mg/kg, ip) sobre la
ansiedad evaluada en el test de «light-dark» en ratones machos de la cepa OF.1. Asimismo, compara-
mos el perfil conductual del GHB con el inducido por mCPP (1 mg/kg, ip), un compuesto con cono-
cidos efectos ansiogénicos. Los animales tratados con GHB pasaron significativamente menos tiempo
en el compartimento iluminado (40 y 80 mg/kg) y más tiempo en el compartimento oscuro (con todas
las dosis), mostrando además una reducción significativa del número total de «rearings», transiciones
y latencia. En los animales que recibieron mCPP se observó un perfil conductual muy similar. En con-
junto, estos resultados indican que el GHB exhibe propiedades ansiogénicas en ratones machos. Se su-
giere que los efectos ansiogénicos del GHB podrían estar relacionados con su capacidad para modular
los receptores GABAérgicos y/o dopaminérgicos.
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ip) by examining its effects of behaviour of male mice in the light-
dark box, a paradigm routinely used to study anxiety-related
behaviour in mouse (Hascoët, Bourin, & Dhnonnchadha, 2001).
Likewise, we also analyzed the effects of mCPP (1 mg/kg) on
anxiety, a compound with an anxiogenic action demonstrated in
rodents (Griebel, Misslin, Pawlowski, & Vogel, 1991).
Materials and methods
Animals
55 albino male mice of the OF.1 strain weighing 25-30 g were
used. Animals were housed in groups of five in plastic cages
(24×13.5×13 cm) under standardized lighting conditions (white
lights on 20:00-8:00), a constant temperature (20 ºC) and food and
tap water available ad libitum, except during behavioural tests.
Cage maintenance was undertaken twice weekly, but never on the
day of testing. Mice were housed 7 days before the experiment.
This experiment was carried out in accordance with the guiding
principles for care and use of Laboratory Animals approved by the
European Communities Council Directive of November 24, 1986
(86/609/EEC).
Drug administration
Five groups of mice were used. Animals were randomly
allocated to one control group (n= 11) receiving physiological
saline and three experimental groups (n= 10-12) receiving GHB
injections. An additional control group of animals treated with
mCPP (1 mg/kg; n= 11) was used. GHB (Sigma Laboratories) was
diluted in physiological saline to provide appropriate doses for
injections and administered in three doses: 40, 80 and 120 mg/kg.
These doses were selected on the basis of previous experiments
carried out in our laboratory with mice. Drugs or saline were
injected intraperitoneally in a volume of 10 ml/kg. Tests were
performed 30 min after injections.
Apparatus
The light-dark aversion test was used according to Belzung et
al. (1987) procedure. The apparatus consisted of two glass boxes
(27×21×24 cm) with an interconnecting grey plastic tunnel (7x10
cm). One of the boxes was painted in black, being weakly lit by a
red 25-W bulb (0 lux). The other box was lit by a 60-W desk lamp
(400 lux) placed 30 cm above the box, which provided the only
laboratory illumination. The floor was lined into 9 cm squares.
The apparatus was positioned on a bench 70 cm above the floor. 
Experimental procedure
The test was performed in a quiet, darkened room. Tests were
carried out between 09:00 and 15:00 h. After injection (saline or
treatment) mice were placed in their home cage. At the beginning
of the test, naïve mice were placed individually in the middle of
the light area facing away from the opening, and were videotaped
during 5 min using a Sony V8 camera. The following parameters
were recorded (Maldonado and Navarro, 2000): (a) number of
exploratory rearings in the light and dark sections; (b) number of
transitions between the lit and dark areas; (c) time spent in the
light and dark areas; (d) latency of the initial movement from the
light to the dark area, and (e) motor activity in both areas. A mouse
was considered to have entered the new area when all four legs
were in this area. None of these animals were used on more than
one occasion. The group order was counterbalanced according to
a Latin square design. At the conclusion of the test period, mice
were returned to their cages, and another animal was placed into
the box. The floor of each box was cleaned between sessions.
Behavioural analysis was performed by a trained experimenter
who was unaware of treatment of the groups.
Data analysis
Nonparametric Kruskal-Wallis tests were used to assess the
variance of the behavioural measures over different treatment
groups. Subsequently, appropriate paired comparisons were
performed using Mann-Whitney U-tests to contrast the parameters
in the different treatment groups. The analysis was performed
using nonparametric statistics since the criteria for parametric
statistics were not met by the data. 
Results
Table 1 illustrates medians (with ranges) of the parameters used.
Kruskall-Wallis analysis showed that there was significant variance
in the parameters of latency, number of transitions, rearings, time
in lit and dark areas, and motor activity (p<0.001-0.05).
Paired comparisons revealed that GHB (80 and 120 mg/kg)
significantly reduced the number of transitions between the lit and
dark areas, as compared with the control group (p<0.01-0.001).
Latency (40 and 80 mg/kg), time spent in lit area (40 and 80
mg/kg), motor activity (120 mg/kg), as well as total number of
rearing (80 and 120 mg/kg), rearings in dark area (120 mg/kg) and
ANXIOGENIC-LIKE EFFECTS OF GAMMA-HYDROXYBUTYRIC ACID (GHB) IN MICE TESTED IN THE LIGHT-DARK BOX 461
Table 1
Effects of GHB on behavioural parameters in the light/dark test in mice
(median values with ranges)
GHB (mg/kg) mCPP (mg/kg)    
Parameters Saline 40 80 120 1
Latency (in sec) ª 20 5.5* 7* 25.5 9*
(2-123) (2-39) (1-87) (1-300) (2-30)
Number of transitions ª 17 11 3* 1* 7*
(2-31) (1-25) (1-29) (0-25) (1-20)
Rearings (lit area) ª 10 5.5* 0* 0* 5*
(0-31) (0-23) (0-26) (0-15) (0-22)
Rearings (dark area)ª 16 15.5 8 3* 11
(0-20) (0-23) (0-25) (0-25) (0-20)
Total number of rearings ª 26 22 16* 4.5* 16.5*
(0-49) (0-46) (0-28) (0-40) (0-42)
Time in lit area (in sec) ª 131 70.5* 69* 97 52.5*
(28-232) (2-110) (1-140) (1-300) (3-119)
Time in dark area (in sec) ª 68 132.5* 118* 109.5* 133*
(29-174) (73-282) (56-293) (0-298) (67-279)  
Motor activity (sec) 65 54.5 49 9* 46.5
(in both areas) ª  (5-85) (4-89) (3-105) (0-77) (0-63)
Kruskal-Wallis test showed significant variance, ª p<0.001-0.05
Differs from control on Mann-Whitney U-tests, * p<0.001-0.05
rearings in lit area (all doses) were also significantly reduced after
treatment with GHB, in comparison with the control group
(p<0.05-0.001). Finally, GHB increased time spent in dark area
(all doses) (p<0.05-0.001). On the other hand, mCPP (1 mg/kg)
significantly reduced latency, number of transitions, rearings and
lit area and total number of rearings as well as time in lit area
(p<0.05-0.001), whereas increased time spent in dark area
(p<0.01), as compared with the control group. 
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Figure 1. Medians (time in sec) in lit area and motor activity (in both areas) in mice treated with saline, GHB (40, 80, 120 mg/kg) or mCPP (1 mg/kg)
Discussion
The light/dark paradigm is based on the innate aversion of
rodents to brightly illuminated areas and on the spontaneous
exploratory behaviour of the animals, applying mild stressors, i.e.
novel environment and light. Thus, in a two compartment box,
rodents will prefer the dark area. Drugs with anxiogenic properties
should increase the time spent in the dark compartment, also
reducing the time spent in the lit compartment. Consequently,
transitions between the compartments and time to explore each of
them are interpreted as indicators of anxiety and have shown to be
sensitive to anxiety-affecting drugs. The Swiss strain of mice has
been found a suitable strain to be used in this test (Hascoët et al.,
2001; Hascoët & Bourin, 1988; Ohl, 2003).
As Table 1 shows, GHB produced a significant decrease in
exploratory activity, in concordance with an anxiogenic-like
profile of the drug. In this sense, GHB-treated mice spent
significantly less time in the lit area (40 and 80 mg/kg) (see figure
1) as well as more time in the dark area (all doses). Likewise, the
total number of ‘rearings’ and transitions was reduced in mice
treated with GHB, as compared with the control group. These
effects were selective for 40 and 80 mg/kg of the drug, whereas
animals receiving 120 mg/kg showed a marked reduction of motor
activity. Therefore, motility was significantly decreased in mice
treated with the highest dose of GHB (120 mg/kg) (see figure 1),
suggesting that, at this dose, the effects of GHB on anxiety are not
specific. This reduction of motor activity has been also described
in other studies with male mice (Navarro et al., 1996; 1998). As a
positive reference, mCPP (1 mg/kg) was tested in the same
experiment. The behavioural profile of GHB (40 and 80 mg/kg)
was very similar to that observed after administration of mCPP, a
compound with an anxiogenic action repeatedly demonstrated in
several animal models of anxiety, including the light-dark test
(Griebel et al., 1991). 
These results are in concordance with a preliminary study in
which GHB also produced anxiogenic-like effects in male mice
tested in the elevated plus maze (Navarro et al., 2000), but they
differ from Schmidt-Mutter et al. (1998), who found an anxiolytic
action of GHB (150 and 250 mg/kg, i.p) in the elevated plus maze
in rats, suggesting an interaction of GHB with the GABA-A
receptor complex since this action was blocked by the
benzodiazepine receptor antagonist, flumazenil. This discrepancy
might represent a species difference. In fact, administration of
drugs such as MDMA induces usually anxiogenic-like effects in
mice (Maldonado & Navarro, 2000; 2001; Navarro & Maldonado,
2002; Navarro et al., 2004), whereas in rats produces anxiolytic or
anxiogenic-like effects, dependent on the basal anxiety level or the
test situation employed (Green & McGregor, 2002). Likewise, the
anxiolytic action of GHB described by Schmidt-Mutter et al.
(1998) was evident with higher doses (150 and 250 mg/kg) than
those used in our experiment (40 and 80 mg/kg). Another possible
explanation for the discrepancy between both studies may be
related with the biphasic effects of GHB on GABA synapses
(Maitre, 1997; Drasbek et al., 2006): at low doses (40 and 80
mg/kg), GHB exerts a feedback inhibition on GABA synapses via
GHB receptors and reduces GABA release (anxiogenic effects),
whereas at higher doses (150-250 mg/kg) GHB receptors are
down-regulated and high doses of GHB interact with GABA-B
receptors, provoking a potentiation of the general GABA tone in
brain (anxiolytic effects). 
On the other hand, GHB interacts with central D2 receptors
(Pedraza et al., 2007). The anxiogenic-like activity found in our
study might be mediated by the dose-related biphasic effect on
dopamine neurotransmission. Low doses of GHB (40 and 80
mg/kg) would exert an excitatory effect on dopamine release,
whereas relatively high doses (150-250 mg/kg) inhibit release
(Howard & Feigembaum, 1997; Pedraza et al., 2007). In fact,
administration of D2 receptor agonists (such as quinpirole) has
been associated with an anxiogenic-like profile in mice (Navarro
& Maldonado, 1999) and D2 receptor antagonists (such as tiapride
or sulpiride) with an anxiolytic-like action (Barry, Costall, Kelly,
& Naylor, 1987). 
In conclusion, GHB (40 and 80 mg/kg) produced a selective
reduction in exploratory activity of mice (rearings and transitions),
also decreasing the time spent in lit area and increasing the time
spent in dark area. This behavioural profile found in the light/dark
test is indicative of an anxiogenic-like action of GHB at these
doses. It is suggested that the anxiogenic effects of GHB could be
related to its ability for modulating GABA and/or dopaminergic
receptors. Although is difficult to extrapolate to humans the results
obtained in mice, our findings suggest that the consumption of
GHB at low doses could be associated to an increase of the
anxiety. Further studies are needed to clarify our understanding of
GHB actions on anxiety.
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